A Study to See if Mesothelin Can Serve as a Marker of Early Lung Cancer

Protocol
13-262
Full Title
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Surgically Treated Early Clinical Stage Lung Adenocarcinoma
Disease Status
Newly Diagnosed
Purpose

The purpose of this study is to see if mesothelin, a protein found in blood and lung tissue, can serve as a marker of early-stage lung cancer. Markers may be used to help diagnose cancer, predict how well a patient will respond to treatment, monitor a patient’s response to treatment, or determine if cancer has returned.

In this study, researchers are comparing mesothelin levels in patients with adenocarcinoma of the lung before surgery to mesothelin levels in patients after surgery. They are examining mesothelin levels in patients’ blood and in lung tissue removed at the time of their cancer surgery. Their goal is to determine if this marker can serve as a predictor of cancer recurrence in patients with lung cancer.

Eligibility

This study includes patients (age 18 and older) with stage IA or IB lung adenocarcinoma who will be having lung cancer surgery and undergo long-term follow-up at Memorial Sloan-Kettering.

For more information about this study and to inquire about eligibility, please contact Dr. Nabil Rizk at 212-639-8357.

Disease(s)
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Locations

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »